Venous thromboembolism in oncology.
Thromboembolic events represent well-recognised complications of neoplastic disease contributing, in a significant manner, to the morbidity and mortality from cancer. The close relationship between the activation of blood coagulation and tumor growth is known since 1865, when Armand Trousseau first described the clinical association between primary or idiopathic venous thromboembolism and an underlying occult malignancy. However, only in the last decades significant advances in this field have been achieved, both on the comprehension of the complex interactions between the tumor and the hemostatic system, and on the prophylaxis and therapy of the thromboembolic manifestations in cancer patients.
Falanga
Anna
A
Department of Hematology-Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy. annafalanga@yahoo.com
Vignoli
Alfonso
A
D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D020246:Venous Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control
D000925:Anticoagulants; D000970:Antineoplastic Agents